Decline in Patient Numbers at Contract Medical Institutions
First written in FY2017. 8 of 24 entries say "Worsened", first in FY2018-Q2. Latest entry: 2026-10-16.
Medinet moved to the "Worse" side of this theme in 2017.
0 other companies' latest entry also says "Materialised".
- FY2024-Q2MitigatedAnnual report
「In the specific cell processing business, the number of commissioned immune-cell processing cases recovered, prices were revised with some business partners, and upfront payments for technology transfers related to commissioned manufacturing,」
The recovery in the number of commissioned immune-cell processing cases was disclosed, indicating an improvement in the risk to cell-processing revenue arising from a decline in patient numbers. - FY2024-Q1MitigatedAnnual report
「In the specific cell processing business, the number of commissioned immune-cell processing cases recovered, prices were revised with some business partners, and upfront payments for technology transfers related to commissioned manufacturing,」
The disclosure states that the number of commissioned immune-cell processing cases related to the company's partner medical institutions recovered, indicating an improvement in the risk to cell-processing revenue arising from a decline in patient numbers. - FY2023MitigatedAnnual report
「In the current fiscal year, the number of patients in Japan at the medical institutions with which we do business has continued to recover, and signs of improvement have begun to emerge.」
The disclosure states that the recovery in the number of patients in Japan at the medical institutions with which the company does business has continued. - FY2023-Q3MitigatedAnnual report
「Since the second half of last year and into the current fiscal year, the number of patients in Japan at the medical institutions with which we do business has continued to recover, and signs of improvement have begun to emerge.」
The disclosure states that the recovery in the number of patients in Japan at the medical institutions with which the company does business has continued, indicating an improvement in the risk of a decline in patient numbers. - FY2023-Q2MitigatedAnnual report
「Since the second half of last year and into the current fiscal year, the number of patients in Japan at the medical institutions with which we do business has continued to recover, and signs of improvement have begun to emerge.」
The disclosure states that the recovery in the number of patients in Japan at the medical institutions with which the company does business has continued, indicating an improvement in the risk of a decline in patient numbers. - FY2023-Q1MitigatedAnnual report
「Meanwhile, from the second half of last year into the first quarter, the number of patients in Japan at the medical institutions with which we do business has been recovering, and signs of improvement have begun to emerge.」
The disclosure states that the number of patients in Japan at the medical institutions with which the company does business is recovering, indicating some improvement in the risk of a decline in patient numbers. Meanwhile, the effects of infectious diseases continue. - FY2022MitigatedAnnual report
「Of net sales of ¥633.672 million for the fiscal year ended September 2022, sales to Medical Corporation Koshikai were ¥383.259 million, representing 60.5% of net sales, indicating that the Company currently has a high level of dependence on that medical corporation.」
Dependence on sales to Koshikai declined from 66.4% previously to 60.5%. However, the Company still described its level of dependence as high. - FY2022-Q3RestatedAnnual report
「Cell-processing sales declined year on year because the slump in inbound patient numbers at affiliated medical institutions continued due to the prolonged COVID-19 pandemic and recovery in the number of domestic patients also remained limited.」
The continuing slump in inbound patient numbers and limited recovery in domestic patient numbers at affiliated medical institutions have been factors in the decline in cell-processing sales. - FY2022-Q2RestatedAnnual report
「The effects of the spread and prolonged duration of COVID-19 have been wide-ranging, including stagnation in economic activity and sluggish personal consumption. The impact has also extended to the Company's affiliated medical institutions and others, and the Company's business remains in a difficult situation.」
The Company continued to explain that the prolonged COVID-19 pandemic had affected affiliated medical institutions and others and that the business environment remained difficult. - FY2021-Q3WorsenedAnnual report
「The impact has also extended to the Company's affiliated medical institutions and others, the outlook for recovery in patient numbers remains uncertain, and the Company's business remains in a difficult situation.」
Due to the prolonged COVID-19 pandemic, the outlook for recovery in patient numbers at affiliated medical institutions has remained uncertain. - FY2021-Q2WorsenedAnnual report
「The slump in inbound patient numbers at affiliated medical institutions caused by the spread of COVID-19 continued,」
The Company stated that the continuing slump in inbound patient numbers at contracted medical institutions led to a significant decline in cell-processing sales and a shift to a segment loss. - FY2021-Q1WorsenedAnnual report
「The slump in inbound patient numbers at affiliated medical institutions caused by the spread of COVID-19 continued,」
The Company stated that the continuing slump in inbound patient numbers at contracted medical institutions led to a significant decline in cell-processing sales and a shift to a segment loss. - FY2020-Q3WorsenedAnnual report
「A decline in cell-processing sales due in part to a decline in inbound patients at affiliated medical institutions caused by the spread of COVID-19」
The decline in inbound patients at contracted medical institutions materialized as an impact of COVID-19 and became a factor in the decline in cell-processing sales. - FY2020-Q2WorsenedAnnual report
「During the cumulative second quarter period, the Company was affected by a decline in inbound patients at medical institutions due to the spread of COVID-19, although」
The decline in inbound patient numbers was actually recorded as an impact of the spread of COVID-19, worsening the risk concerning recovery in patient numbers at contracted medical institutions. - FY2020-Q1RestatedAnnual report
「Although the number of patients, mainly inbound patients, is increasing, the recovery in patient numbers is expected to remain limited owing to changes in the market environment for cancer immunotherapy and other factors.」
The Company continued to explain that patient numbers at contracted medical institutions had increased in some cases, while recovery remained limited. - FY2019-Q3RestatedAnnual report
「Although patient numbers increased at some medical institutions contracted for the manufacture of specified cell-processed products, recovery remained limited due to changes in the market environment in the cancer immunotherapy field and other factors,」
The Company continued to explain that, although patient numbers increased at some contracted medical institutions, recovery remained limited due to changes in the market environment in the cancer immunotherapy field. - FY2019-Q2RestatedAnnual report
「Although patient numbers increased at some medical institutions contracted for the manufacture of specified cell-processed products, recovery remained limited due to changes in the market environment in the cancer immunotherapy field and other factors,」
The Company continued to explain that, although patient numbers at contracted medical institutions increased at some locations, recovery remained limited due to changes in the market environment in the cancer immunotherapy field. - FY2019-Q1Patient numbers increased at some institutions, but recovery remained limitedAnnual report
「Although patient numbers increased at some medical institutions contracted for the manufacture of specified cell-processed products, recovery remained limited due to changes in the market environment in the cancer immunotherapy field and other factors,」
Patient numbers at contracted medical institutions increased at some locations, but the Company explained that recovery remained limited due to changes in the market environment in the cancer immunotherapy field. - FY2018-Q3WorsenedAnnual report
「During the first 3 quarters of the current consolidated fiscal year, patient numbers at medical institutions contracted for the manufacture of specified cell-processed products continued to decline due to changes in the market environment in the cancer immunotherapy field and other factors. As a result, net sales were ¥770 million, down ¥544 million year on year, or 41.4%.」
The continuing decline in patient numbers at contracted medical institutions was a factor in the 41.4% year-on-year decline in total sales, including the cell-processing business. - FY2018-Q2WorsenedAnnual report
「Net sales were ¥541 million, down ¥352 million year on year, or 39.4%, due in part to a decline in patient numbers at medical institutions that had entered into contracts for the outsourced manufacture of specified cell-processed products.」
The decline in patient numbers at contracted medical institutions recurred and was a factor in the 39.4% year-on-year decline in cell-processing sales. - FY2018-Q1MaterialisedAnnual report
「Net sales were ¥295 million, down ¥156 million year on year, or 34.6%, due in part to a decline in patient numbers at medical institutions that had entered into contracts for the outsourced manufacture of specified cell-processed products.」
The decline in patient numbers at contracted medical institutions again occurred and was a factor in the decrease in sales of specified cell-processed products and total sales. - FY2017MaterialisedAnnual report
「Sales from the comprehensive immune cell therapy support service declined from the previous consolidated fiscal year, partly because the number of patients at contracted medical institutions decreased.」
A decline in patient numbers at contracted medical institutions actually reduced sales from the core comprehensive immune cell therapy support service.